Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized Pyruvate (13C) MRI in Prostate Cancer on Active Surveillance
NCT03933670Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Jul 2018
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of [1-13C]pyruvate in prostate cancer (PCa), sponsored by University of California, San Francisco. Started Jul 2018; status: recruiting.
02
Drugs
[1-13C]pyruvate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03933670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933670.